Pharmafile Logo

News and Press Releases

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa

Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV 10 October 2025 -- Cairo, Egypt; Berlin, Germany; and New York, New York -- IAVI,...

Category: Biotechnology, Drug Delivery, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 10, 2025

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin

Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting

KRAS-specific synthetic lethal targets identified through Ryvu's ONCO Prime platform show promising potential for new therapeutic options for colorectal cancer (CRC) patients RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor,...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

6 March 2025 -- Berlin, Germany -- ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 6, 2025

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded

February 04, 2025 – Berlin, Germany – Biotech Newswire / -- ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded...

Category: Biotechnology
Posted: February 5, 2025

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin

Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows

4 June 2024 - Cambridge, UK - Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-CellectPLUS. In conjunction with...

Category: Biotechnology, Drug Discovery
Posted: June 4, 2024

Sphere Fluidics
info@spherefluidics.com
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom

ModeX Therapeutics Leverages ProBioGen’s Expertise for Accelerated COVID-19 Antibody Development

29 May 2024 -- Berlin, Germany -- ProBioGen, a leading contract development and manufacturing organisation (CDMO), known for its innovative solutions in cell engineering and bioprocessing excellence, announces a pivotal...

Category: BioManufacturing, Biotechnology, Pharmaceutical
Posted: May 29, 2024

ModeX Therapeutics
info@modextx.com
20 Riverside Road Weston, MA 02493

ProBioGen Announces Change in Management

30 April 2024 -- Berlin, Germany -- ProBioGen AG, a premier contract development and manufacturing organisation (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP...

Category: BioManufacturing, Other
Posted: April 30, 2024

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC for Ground-breaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology

13 March 2024 -- Berlin, Germany -- ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, is pleased to announce the execution of services and license agreements...

Category: Biotechnology
Posted: March 13, 2024

ProBioGen
info@probiogen.de
Herbert-Bayer-Straße 8 13086 Berlin

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring 5 October 2023 -- California, US -- Bio-Rad Laboratories,...

Category: Drug Discovery
Posted: October 5, 2023

Bio-Rad
UK_contact@bio-rad.com
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET